[12] Patent
[11] Patent No.:GC0007664  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126566
Date of the Decision to Grant the Patent:29/Apr/2018

[21] Application No.:GCC/P/2006/6800

[22] Filing Date:23/8/2006

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
25/8/2005
60/711,442

[72] Inventors:1- Qi-Ying Hu،2- Lauren G. Monovich،3- Erik Meredith،4- Fariborz Firooznia،5- Julien Papillon،6- Gary Michael Ksander

[73] Owner: Recordati AG, Lindenstrasse 8, Baar, Switzerland

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

  

[51]IPC:
Int. Cl.: A61K 31/50; A61P 35/00; C07D 471/04, 487/04 (2006.01)

[56] Cited Documents:

-EP 0426225 A2 (JANSSEN PHARMACEUTICA NV [BE]) 8 May 1991
-WO 9315079 A (JANSSEN PHARMACEUTICA NV [BE]) 5 August 1993
-WO 2004046145 A (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; FIROOZNIA FARIBORZ [US]) 3 June 2004
 
Examiner: PH. Nada M. AlBehaiji

[54] IMIDAZOLE DERIVATIVES USED AS ALDOSTERONE AND AROMATASE INHIBITORS
[57] Abstract: The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy. Finally, the present invention also provides a pharmaceutical composition
No. of claims: 9


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.